 |
The Journal of Neuroscience, July 13, 2005, 25(28):6594-6600; doi:10.1523/JNEUROSCI.0970-05.2005
Previous Article | Next Article 
Neurobiology of Disease
Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice
Dong-Kug Choi,1,5
Subramaniam Pennathur,4
Celine Perier,1
Kim Tieu,1
Peter Teismann,1
Du-Chu Wu,1
Vernice Jackson-Lewis,1
Miquel Vila,1
Jean-Paul Vonsattel,2
Jay W. Heinecke,4 and
Serge Przedborski1,2,3
1Neuroscience Research Laboratories of the Movement Disorder Division, Department of Neurology, 2Department of Pathology, and 3Center for Neurobiology and Behavior, Columbia University, New York, New York 10032, 4Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington 98195, and 5Department of Biotechnology, Konkuk University, Chungju-City, Chungbuk 380-701, Korea
Parkinson's disease (PD) is characterized by a loss of ventral midbrain dopaminergic neurons, which can be modeled by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Inflammatory oxidants have emerged as key contributors to PD- and MPTP-related neurodegeneration. Here, we show that myeloperoxidase (MPO), a key oxidant-producing enzyme during inflammation, is upregulated in the ventral midbrain of human PD and MPTP mice. We also show that ventral midbrain dopaminergic neurons of mutant mice deficient in MPO are more resistant to MPTP-induced cytotoxicity than their wild-type littermates. Supporting the oxidative damaging role of MPO in this PD model are the demonstrations that MPO-specific biomarkers 3-chlorotyrosine and hypochlorous acid-modified proteins increase in the brains of MPTP-injected mice. This study demonstrates that MPO participates in the MPTP neurotoxic process and suggests that inhibitors of MPO may provide a protective benefit in PD.
Key words: MPTP; Parkinson's disease; oxidative stress; inflammation; neuroprotection; nitrotyrosine
Received March 11, 2005;
revised May 16, 2005;
accepted May 31, 2005.
This article has been cited by other articles:

|
 |

|
 |
 
H.-M. Gao, P. T. Kotzbauer, K. Uryu, S. Leight, J. Q. Trojanowski, and V. M.-Y. Lee
Neuroinflammation and Oxidation/Nitration of {alpha}-Synuclein Linked to Dopaminergic Neurodegeneration
J. Neurosci.,
July 23, 2008;
28(30):
7687 - 7698.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. D. Reynolds, R. Banerjee, J. Liu, H. E. Gendelman, and R. L. Mosley
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease
J. Leukoc. Biol.,
November 1, 2007;
82(5):
1083 - 1094.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-P. Liang, J. Huang, R. Fulton, B. J. Day, and M. Patel
An Orally Active Catalytic Metalloporphyrin Protects against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Neurotoxicity In Vivo
J. Neurosci.,
April 18, 2007;
27(16):
4326 - 4333.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. W. Castellani, J. J. Chang, X. Wang, A. J. Lusis, and W. F. Reynolds
Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males
J. Lipid Res.,
July 1, 2006;
47(7):
1366 - 1377.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|